Home › For J&J Prostate Cancer Is PARP For The Course
 

Keywords :   


For J&J Prostate Cancer Is PARP For The Course

2016-04-07 23:45:50| Food - Topix.net

Johnson & Johnson addressed two issues with one relatively small $35m payment: its position in prostate cancer and absence from PARP inhibition. The big pharma group locked up one of just two unpartnered assets in this rejuvenated class and has chosen to focus its work in prostate cancer, where Zytiga might soon run out of market exclusivity.

Tags: the cancer prostate prostate cancer

Category:Food and Related Products

Latest from this category

All news
»
06.10Hurricane Milton Public Advisory Number 5A
06.10Summary for Hurricane Milton (AT4/AL142024)
06.10Atlantic Tropical Weather Outlook
06.10Eastern North Pacific Tropical Weather Outlook
06.10Glatfelter Develops Biobased Espresso Lid Material
06.10Tropical Storm Milton Potential Storm Surge Flooding Map
06.10Tropical Storm Milton Probabilistic Storm Surge Graphics
06.10Firms urge mayor to rethink congestion charge plan
More »